Literature DB >> 23456446

Role of microangiopathy in diabetic cardiomyopathy.

Adriana Adameova1, Naranjan S Dhalla.   

Abstract

Although heart disease due to diabetes is mainly associated with complications of the large vessels, microvascular abnormalities are also considered to be involved in altering cardiac structure and function. Three major defects, such as endothelial dysfunction, alteration in the production/release of hormones, and shift in metabolism of smooth muscle cells, have been suggested to produce damage to the small arteries and capillaries (microangiopathy) due to hyperglycemia, and promote the development of diabetic cardiomyopathy. These factors may either act alone or in combination to produce oxidative stress as well as changes in cellular signaling and gene transcription, which in turn cause vasoconstriction and structural remodeling of the coronary vessels. Such alterations in microvasculature produce hypoperfusion of the myocardium and thereby lower the energy status resulting in changes in Ca(2+)-handling, apoptosis, and decreased cardiac contractile force. This article discusses diabetes-induced mechanisms of microvascular damage leading to cardiac dysfunction that is characterized by myocardial dilatation, cardiac hypertrophy as well as early diastolic and late systolic defects. Metabolic defects and changes in neurohumoral system due to diabetes, which promote disturbances in vascular homeostasis, are highlighted. In addition, increase in the vulnerability of the diabetic heart to the development of heart failure and the signaling pathways integrating nuclear factor κB and protein kinase C in diabetic cardiomyopathy are also described for comparison.

Entities:  

Mesh:

Year:  2014        PMID: 23456446     DOI: 10.1007/s10741-013-9378-7

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  103 in total

1.  Effects of endothelin receptor blockade on hypervasoreactivity in streptozotocin-diabetic rats: vessel-specific involvement of thromboxane A2.

Authors:  Emi Arikawa; Claudia Cheung; Inna Sekirov; Mary L Battell; Violet G Yuen; John H McNeill
Journal:  Can J Physiol Pharmacol       Date:  2006 Aug-Sep       Impact factor: 2.273

2.  Elevated plasma endothelin in patients with diabetes mellitus.

Authors:  K Takahashi; M A Ghatei; H C Lam; D J O'Halloran; S R Bloom
Journal:  Diabetologia       Date:  1990-05       Impact factor: 10.122

3.  Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats.

Authors:  H A Baba; T Iwai; M Bauer; M Irlbeck; K W Schmid; H G Zimmer
Journal:  J Mol Cell Cardiol       Date:  1999-02       Impact factor: 5.000

4.  Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density.

Authors:  Alfred P McQueen; Dongfang Zhang; Ping Hu; Leanne Swenson; Ying Yang; Vlad G Zaha; James L Hoffman; Ui Jeong Yun; Gopa Chakrabarti; Zhengming Wang; Kurt H Albertine; E D Abel; Sheldon E Litwin
Journal:  J Mol Cell Cardiol       Date:  2005-10-10       Impact factor: 5.000

5.  Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation.

Authors:  L Virág; P Jagtap; E Szabó; J G Mabley; L Liaudet; A Marton; D G Hoyt; K G Murthy; A L Salzman; G J Southan; C Szabó
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

Review 6.  Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.

Authors:  G Boden
Journal:  Diabetes       Date:  1997-01       Impact factor: 9.461

Review 7.  Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications.

Authors:  Zhi You Fang; Johannes B Prins; Thomas H Marwick
Journal:  Endocr Rev       Date:  2004-08       Impact factor: 19.871

Review 8.  Peroxynitrite: biochemistry, pathophysiology and development of therapeutics.

Authors:  Csaba Szabó; Harry Ischiropoulos; Rafael Radi
Journal:  Nat Rev Drug Discov       Date:  2007-08       Impact factor: 84.694

Review 9.  Endothelial dysfunction in insulin resistance and type 2 diabetes.

Authors:  P-A Jansson
Journal:  J Intern Med       Date:  2007-08       Impact factor: 8.989

10.  Additive effects of hyperinsulinemia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo.

Authors:  R R Russell; R Yin; M J Caplan; X Hu; J Ren; G I Shulman; A J Sinusas; L H Young
Journal:  Circulation       Date:  1998-11-17       Impact factor: 29.690

View more
  32 in total

Review 1.  Mitochondria as a target of cardioprotection in models of preconditioning.

Authors:  Magdaléna Jašová; Ivana Kancirová; Iveta Waczulíková; Miroslav Ferko
Journal:  J Bioenerg Biomembr       Date:  2017-07-20       Impact factor: 2.945

2.  Transplanted bone marrow mesenchymal stem cells protects myocardium by regulating 14-3-3 protein in a rat model of diabetic cardiomyopathy.

Authors:  Xiaoyan Dong; Fen Zhu; Qun Liu; Yuanheng Zhang; Jun Wu; Wen Jiang; Lei Zhang; Shuguang Dong
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Left ventricular systolic dysfunction predicts long-term major microvascular complication outcomes in type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications (EDC) study of childhood onset diabetes.

Authors:  Jingchuan Guo; Rachel G Miller; Tina Costacou; William P Follansbee; Trevor J Orchard
Journal:  J Diabetes Complications       Date:  2017-12-28       Impact factor: 2.852

4.  Association of Cardiovascular Risk Factors and Myocardial Fibrosis With Early Cardiac Dysfunction in Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.

Authors:  Anderson C Armstrong; Bharath Ambale-Venkatesh; Evrim Turkbey; Sirisha Donekal; Elzbieta Chamera; Jye-Yu Backlund; Patricia Cleary; John Lachin; David A Bluemke; João A C Lima
Journal:  Diabetes Care       Date:  2016-12-16       Impact factor: 19.112

5.  High-sensitivity cardiac troponin T and severity of cerebral white matter lesions in patients with acute ischemic stroke.

Authors:  Regina von Rennenberg; Bob Siegerink; Ramanan Ganeshan; Kersten Villringer; Wolfram Doehner; Heinrich J Audebert; Matthias Endres; Christian H Nolte; Jan F Scheitz
Journal:  J Neurol       Date:  2018-10-11       Impact factor: 4.849

6.  The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts.

Authors:  Young Hee Shin; Jeong Jin Min; Jong-Hwan Lee; Eun-Hee Kim; Go Eun Kim; Myung Hee Kim; Jeong Jin Lee; Hyun Joo Ahn
Journal:  Heart Vessels       Date:  2016-12-24       Impact factor: 2.037

7.  Characteristics of Myocardial Perfusion in Type 2 Diabetes Mellitus and Its Association with Left Ventricular Diastolic Dysfunction: A Study of Myocardial Contrast Echocardiography.

Authors:  Yi Liu; Jing Ma; Jia Guo; Hao Lu; Yan Zhang; Yilei Chen
Journal:  Int J Gen Med       Date:  2021-11-02

Review 8.  Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.

Authors:  Guanghong Jia; Vincent G DeMarco; James R Sowers
Journal:  Nat Rev Endocrinol       Date:  2015-12-18       Impact factor: 43.330

9.  Disruption of type 5 adenylyl cyclase prevents β-adrenergic receptor cardiomyopathy: a novel approach to β-adrenergic receptor blockade.

Authors:  Lin Yan; Stephen F Vatner; Dorothy E Vatner
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-05       Impact factor: 4.733

10.  Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: potential role of attenuated oxidative stress and altered contractile protein expression.

Authors:  Anindita Das; David Durrant; Saisudha Koka; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  J Biol Chem       Date:  2013-12-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.